2 ratings / 4.5 average

Treatment – Metastatic and Advanced Disease

Baselga J, Campone M, Piccart M et al.

Massachusetts General Hospital Cancer Center, Boston, MA, USA.

 N Engl J Med 2012;366:520–9.

Lukas Schwentner’s review: In this study, the authors investigated the role of everolimus, a mammalian target of rapamycin (mTor) inhibitor, assigned in combination with exemestane for advanced hormone receptor-positive breast cancer. There is a lot of evidence that the mTor pathway is involved in endocrine resistance in breast cancer. The primary endpoint of this Phase III trial was progression-free survival (PFS) and the secondary endpoints were survival, safety, and toxicity.

Return to top


Our most popular articles